Hereditary ATTR (hATTR) Amyloidosis Market Analysis, Leading Companies, Emerging Drugs and Epidemiology Forecast

July 10 16:00 2020
Hereditary ATTR (hATTR) Amyloidosis Market Analysis, Leading Companies, Emerging Drugs and Epidemiology Forecast

Delveinsight Business Research
DelveInsight’s “Hereditary ATTR (hATTR) Amyloidosis Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Hereditary ATTR (hATTR) Amyloidosis, historical and forecasted epidemiology as well as the Hereditary ATTR (hATTR) Amyloidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Hereditary transthyretin amyloidosis (hATTR), an inherited, rapidly progressive, and life-threatening disease, is caused by a mutation in the transthyretin (TTR) gene that results in misfolded TTR proteins accumulating as amyloid fibrils in multiple sites, including the nerves, heart, and gastrointestinal tract. TTR protein is produced primarily in the liver and is usually a carrier for retinol-binding protein—one of the media used to transport vitamin A around the body. hATTR amyloidosis involves many systems in the body and can result in a wide variety of symptoms, including sensory and motor, autonomic (e.g., diarrhea, hypotension, erectile dysfunction), and cardiac symptoms.



Get FREE sample copy at:


The Hereditary ATTR (hATTR) Amyloidosis market report also covers emerging drugs, current treatment practices, Hereditary ATTR (hATTR) Amyloidosis market share of the individual therapies, current and forecasted Hereditary ATTR (hATTR) Amyloidosis Market Size from 2017 to 2030 segmented by seven major markets. The report provides a detailed current Hereditary ATTR (hATTR) Amyloidosis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market. 


Hereditary ATTR (hATTR) Amyloidosis Market Key Facts

In 2017, the total diagnosed prevalent population of hATTR in the 7MM was 11,330.

hATTR is segmented into two groups, i.e., Familial Amyloid Polyneuropathy (FAP) and Familial Amyloid Cardiomyopathy (FAC) cases. In 2017, there were 5,241, and 6,089 diagnosed prevalent cases of FAP and FAC, respectively, in the 7MM.

Among the EU5 countries, Italy has the highest diagnosed prevalent population of hATTR with 1,216 cases, followed by France with a diagnosed prevalent population of 1,086 in 2017. On the other hand, the United Kingdom has the lowest prevalent population, with 239 cases in 2017.


Key Benefits of Hereditary ATTR (hATTR) Amyloidosis Market Report

  • Hereditary ATTR (hATTR) Amyloidosis market report provides an in-depth analysis of Hereditary ATTR (hATTR) Amyloidosis Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.

  • The Hereditary ATTR (hATTR) Amyloidosis market report will help in developing business strategies by understanding the Hereditary ATTR (hATTR) Amyloidosis Market trends & developments, key players and future market competition that will shape and drive the Hereditary ATTR (hATTR) Amyloidosis market in the upcoming years.

  • The Hereditary ATTR (hATTR) Amyloidosis market report covers Hereditary ATTR (hATTR) Amyloidosis current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.

  • The report provides a detailed assessment of the Hereditary ATTR (hATTR) Amyloidosis market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population,  comparative analysis of pipeline products with detailed clinical profiles, and other factors. 


Hereditary ATTR (hATTR) Amyloidosis Market

The Hereditary ATTR (hATTR) Amyloidosis market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Hereditary ATTR (hATTR) Amyloidosis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology. 

The report gives a thorough detail of Hereditary ATTR (hATTR) Amyloidosis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders. 


Hereditary ATTR (hATTR) Amyloidosis Epidemiology

The Hereditary ATTR (hATTR) Amyloidosis epidemiology section covers insights about historical and current Hereditary ATTR (hATTR) Amyloidosis patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  


Hereditary ATTR (hATTR) Amyloidosis Drugs Uptake and Key Market Players

The Hereditary ATTR (hATTR) Amyloidosis Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hereditary ATTR (hATTR) Amyloidosis market or expected to get launched in the market during the study period. The analysis covers Hereditary ATTR (hATTR) Amyloidosis market uptake by drugs; patient uptake by therapies; and sales of each drug.    

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.


The Key Companies in the Hereditary ATTR (hATTR) Amyloidosis Market includes:

Alnylam Pharmaceuticals

Prothena Corporation

Ionis Pharmaceuticals



and many others


Table of Content

1. Key Insights

2. Executive Summary 

3. Hereditary ATTR (hATTR) Amyloidosis Competitive Intelligence Analysis

4. Hereditary ATTR (hATTR) Amyloidosis Market Overview at a Glance

5. Hereditary ATTR (hATTR) Amyloidosis Disease Background and Overview

6. Hereditary ATTR (hATTR) Amyloidosis Patient Journey

7. Hereditary ATTR (hATTR) Amyloidosis Epidemiology and Patient Population

8. Hereditary ATTR (hATTR) Amyloidosis Treatment Algorithm, Current Treatment, and Medical Practices

9. Hereditary ATTR (hATTR) Amyloidosis Unmet Needs

10. Key Endpoints of Hereditary ATTR (hATTR) Amyloidosis Treatment

11. Hereditary ATTR (hATTR) Amyloidosis Marketed Products

12. Hereditary ATTR (hATTR) Amyloidosis Emerging Therapies

13. Hereditary ATTR (hATTR) Amyloidosis Seven Major Market Analysis

14. Attribute Analysis

15. Hereditary ATTR (hATTR) Amyloidosis Market Outlook (7 major markets)

16. Hereditary ATTR (hATTR) Amyloidosis Access and Reimbursement Overview

17. KOL Views on the Hereditary ATTR (hATTR) Amyloidosis Market.

18. Hereditary ATTR (hATTR) Amyloidosis Market Drivers

19. Hereditary ATTR (hATTR) Amyloidosis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer


About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States